In vitro Evaluation of Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses

Text-only Preview

American
Journal
of
Health
Research
2015; 3(6): 338-343
Published online November 9, 2015 (http://www.sciencepublishinggroup.com/j/ajhr)
doi: 10.11648/j.ajhr.20150306.14
ISSN: 2330-8788 (Print); ISSN: 2330-8796 (Online)
In vitro Evaluation of Biofield Treatment on Viral Load
Against Human Immunodeficiency-1 and Cytomegalo
Viruses
Mahendra Kumar Trivedi
1
, Alice Branton
1
, Dahryn Trivedi
1
, Gopal Nayak
1
,
Sambhu Charan Mondal
2
, Snehasis Jana
2, *
1
Trivedi Global Inc., Henderson, USA
2
Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India
Email address:
To cite this article:
Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana. In vitro Evaluation of
Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses. American Journal of Health Research.
Vol. 3, No. 6, 2015, pp. 338-343. doi: 10.11648/j.ajhr.20150306.14
Abstract:
Viral load quantification is the amount o f particular viral DNA or RNA in a blood samples. It is one of the
surrogate biomarker of AIDS. High viral load indicates that the immune system is failed to fight against viruses. The aim of
this study was to evaluate the impact of biofield treatment on HIV-1 and HCMV in terms of viral loads as surrogate marker.
The viral load assay was performed on stored stock cultures of HIV infected human plasma sa mples before and after 7 days of
biofield treatment using Roche COBAS
®
AMPLICOR analyzer. Viral load (HIV-1 RNA and HCMV DNAaemia) was
considered as surrogate marker for assessment of the impact of Mr. Trivedi’s biofield treatment in HIV infected stored pla sma
samples. The viral load quantification of HIV-1 RNA in infected stored plasma samples was significantly reduced by 65% in
biofield treated group as compared to control. Additionally, viral load of HCMV DNAaemia in infected stored plasma samples
was also reduced by 80% in the biofield treated group as compared to control. Because, children are more prone to HCMV
infection a nd adults ar e generally liable to suffer from HIV-1 infection. As the b iofield treatment has reduced HCMV
DNAaemia, it could be beneficial for HIV infected children populations. Altogether, data suggest that biofield treatment has
significantly reduced the viral load quantification in HIV-1 and HCMV infected stored plasma samples and could be a suitable
alternative treatment strategy for AIDS patients in near future.
Keywords:
Human Immune Deficiency Virus, Biofield Treatment, Cytomegalo Virus, Viral Load, HIV RNA,
HCMV DNAaemia, AIDS, Surrogate Biomarker
1. Introduction
Human immunodeficienc y virus type 1 (HIV-1) is the
main causative agent of acquired immune deficie ncy
syndrome (AIDS) [1]. HIV is a wor ldwide pandemic
disease, and the number of infe cted peoples ar ound the
world incr easing da y by day. Recent e stimate fro m World
Health Organization (WHO) shows tha t 16.3 million people
have died from AIDS since t he beginning of the epidemic.
Currently, around 34.3 million people alive wit h HIV
infection, in which approx imately 7% a re young ad ults [2],
infected with HIV type 1 (HIV-1) acros s the mucosal
surfaces or by direct ino culation. T he virus first attacks to
dendritic cells (DCs) and subsequently sprea ds to cluster of
differentiation - 4 (CD
4+
) T lymphocytes [3]. Human
cytomegalovirus (HCMV) is a verna cular name of the
human herpes virus - 5, a highl y host-speci fic virus of the
herpesviridae family rarely causes symptoms. The target
DNA sequence is specific, located within the HCMV DNA
polymerase gene, and is not homo logous to other members
of the human h erpes virus fam ily. The pregnant women and
immune weakened persons are highly prone to acquire
infection by HCMV viru s. It spreads thro ugh various body
fluids, such as blood, urine, saliva, semen, and breast milk .
It may also causes serious morbidity and mortality in organ
transplant recipien ts, immunocompromise d, HIV infected
patients and congenitall y infected newborns [4]. H CMV is
mainly prevalent in kid ney transplant patie nts. The viral
‘threshold load’ is very sensitive and specific for predicting
339 Mahendra Kumar Trivedi et al.:
In vitro Evaluation of Biofield Treatment on Viral Load Against Human
Immunodeficiency-1 and Cytomegalo Viruses
both white blood cell and platele t quantific ation in kidney
transplant patie nts. The thr eshold value is more th an 10000
copies/mL co nsidered as HCMV infectio n [5]. In infected
adults, HIV viral load is predict ive of pr ogression to AIDS
[6, 7] and HCMV DNAaemia pre dicts progression to
disease, particula rly retinitis [8]. Several s tudy reports have
confirmed the r elation between HIV-1 vi ral load and
HCMV DNAaemia levels in terms of predic tion of disease
(AIDS) pro gression in both adults [6, 7] and children
[9,10]. Rese archers found an excellent cor relation be tween
two viruses i.e. HIV in fected adu lts are highly predictable
for the devel opment of HCM V end organ disease [11].
Hence, in this experiment th e dual viruses we re taken into
consideration as a rational. Immuno modulatory therapies
are curre ntly used against HIV-1 infections which include
mycophenolate mofetil, cyclosporin e, inte rleukin-2 (IL-2),
and va rious vaccines [12 ]. Alth ough several trea tment
strategie are availabl e against AIDS patients i nfected by
HIV-1 such as antiretrovir al agents and vaccination. B ut
some difficulties are a lso present. Based o n above lacunas,
there is a need o f an alternative wa y which may be use ful to
determine the viral loads by either enhanc ing the
application of existing agents or by means of some
alternative strategy or deve loping new drugs. Biofield
treatment is an alternative appr oach which may be useful to
improve these u nfilled space as sociated with AI DS infected
patients. Mr. Tri vedi’s un ique biofield treatment (The
Trivedi effect
®
) has been extensively contrib utes in
scientific co mmunities in several fields [13-16] . Therefore,
authors interested, to evaluate the impact of b iofield
treatment on viral load in HIV a nd HCMV infe cted plasma
samples.
2. Materials and Methods
The viral samples (HIV-1 and HCMV) as stored stock
cultures were procured fro m department of micro biology
laboratory, P.D. Hinduja National Hospital and Medical
Research Centre, Mumbai. The viral load assay was
performed on HIV patients stored plasma samples be fore and
after treatment using Roche COBAS AMPLICOR analyzer
according to manufacturer’s instructions.
2.1. Biofield Treatment Strategy and Experimental Design
Two sets of each viral samples (HIV-1; 31 samples and
HCMV; 5 samples) of HIV and HCMV infected stored
plasma were used in this experiment for determination of
viral load quantification. The first sets of both viral samples
were considered as control. No treatment was given to these
sets. The second sets of both viral samples were subjected to
Mr. Mahendra Trivedi’s biofield treatment, co nsidered as
treated group. Both control and treated samples were
analyzed after 7 days for viral load quantification in as per
the standard protocols. An optimum precautionary measure
was taken to maintain the cold chain throughout the
experiment. The differences of viral load quantification
before and after the treatment were noted.
2.2. COBAS
®
Amplicor HIV-1 Monitor Test
The COBAS
®
amplicor HIV-1 monitor test (v1.5) is an in
vitro nucleic acid amplification test approved by food and
drug administration (FDA) for the quantification of HIV-1
RNA in human plasma on the COBAS AMPLICOR
TM
analyzer. This technique is a gold standard automated
solution for testing of HIV-1 viral loads in major
pharmaceutical trials [17].
2.3. COBAS
®
Amplicor CMV Monitor Test
The COB AS® amp licor CMV monitor test is FDA
approved in vitr o amplification t est for the qu antification of
HCMV DNA in human plasma on t he COBAS
AMPLICORTM a nalyzer. Thi s is an automated, sensitive,
reliable, and speci fic metho d for quantificatio n of
cytomegalo viral loads in HCMV infect ed patients wit h
high productivity (600 co pies/mL to 100,000 copies/ mL)
[18].
3. Results and Discussion
Viral load (Fig. 1) means the a mount of HIV RNA or
HCMV DNA particles per milliliter of blood sample. Higher
the viral titer indicates that the immune system is failed to
fight against HIV or HCMV.
The viral loads of HI V-1 and HCMV ex pressed as
copies/ml are shown in Table 1 a nd 2, resp ectively. H IV
RNA and HCMV DNA (vi ral load) and CD
4+
T lymphocyte
cell c ount a re t he two surro gate markers of HIV pa tients
[19].
All the values are expressed as (IU/mL); Ser ial number 1-
31 denoted as viral stock human plasma samples.
Figure 1. Schematic diagram related to viral load and its risk manifestation.
American Journal of Health Research 2015; 3(6): 338-343 340
Table 1. Viral load of human immunodeficiency virus type-1 (HIV-1) in infected stored plasma samples.
S. No. Viral load Log10 (Control) Viral load Log10 (Treatment) Change in Viral Load Log10
(Treatment) - Log10 (Control)
Control Treatment
1. 91900 4.96 18500 4.27 -0.70
2. 179000 5.25 69300 4.84 -0.41
3. 159000 5.20 121000 5.08 -0.12
4. 10300 4.01 4110 3.61 -0.40
5. 107000 5.03 103000 5.01 -0.02
6. 1650000 6.22 3320000 6.52 0.30
7. 172000 5.24 122000 5.09 -0.15
8. 7820 3.89 2320 3.37 -0.53
9. 1540 3.19 3060 3.49 0.30
10. 34400 4.52 1320 3.12 -1.40
11. 69300 4.84 174000 5.24 0.40
12. 2190 3.34 1760 3.25 -0.09
13. 1860 3.27 881 2.94 -0.32
14. 17400 4.24 8690 3.94 -0.30
15. 216000 5.33 297000 5.47 0.14
16. 321000 5.51 440000 5.64 0.14
17. 17400 4.24 17400 4.24 0.00
18. 9840 3.99 8540 3.93 -0.06
19. 10300 4.01 3140 3.50 -0.52
20. 99200 5.00 65700 4.82 -0.18
21. 1650000 6 .22 2 900000 6.46 0.24
22. 290000 5.46 291000 5.46 0.00
23. 156000 5.19 401000 5.60 0.41
24. 3070000 6 .49 1 450000 6.16 -0.33
25. 587000 5.77 807000 5.91 0.14
26. 36500 4.56 22100 4.34 -0.22
27. 138000 5.14 68400 4.84 -0.30
28. 6560 3.82 4230 3.63 -0.19
29. 1900000 6 .28 2 580000 6.41 0.13
30. 32800 4.52 20800 4.32 -0.20
31. 42700 4.63 18600 4.27 -0.36
All the values are expressed as (IU/mL); Serial number 1-31 denoted as viral stock human plasma samples.
Table 2. Viral loads of human cytomegalo virus (HCMV) in infected stored plasma samples.
S. No. Viral load L og10 (Control)
Viral load Log10 (Treatment) Change in Viral Load Log10
(Treatment) - Log10 (Control)
Control Treatment
1. 86900 4.94 78200 4.89 -0.05
2. 18100 4.26 8760 3.94 -0.32
3. 40500 4.61 35000 4.54 -0.06
4. 1570 3.20 1360 3.13 -0.06
5. 697 2.84 <600 2.78 -0.07
All the values are expressed as (IU/mL); Serial number 1-5 denoted as viral stock human plasma samples.
Figure 2. Percentage change of viral load of A. (HIV RNA) in human immunodeficiency virus type-1 (HIV-1) and B. (HCMV DNA) in human cytomegalo virus
(HCMV) after biofield treatment.